Journal of Endocrinology

References

1. ↵
   1. Ahloulay M,
   2. Bouby N,
   3. Machet F,
   4. Kubrusly M,
   5. Coutaud C &
   6. Bankir L

   1992 Effects of glucagon on glomerular filtration rate and urea and water excretion. American Journal of Physiology. Renal Physiology 263 F24–F36.
2. ↵
   1. Ahren B

   2000 Autonomic regulation of islet hormone secretion – implications for health and disease. Diabetologia 43 393–410.
3. ↵
   1. Ahren B &
   2. Lundquist I

   1982 Influences of gastro-intestinal polypeptides and glucose on glucagon secretion induced by cholinergic stimulation. Hormone and Metabolic Research 14 529–532.
4. ↵
   1. Ahren B,
   2. Veith RC &
   3. Taborsky GJ Jr.

   1987 Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon. Endocrinology 121 323–331.
5. ↵
   1. Akesson B,
   2. Panagiotidis G,
   3. Westermark P &
   4. Lundquist I

   2003 Islet amyloid polypeptide inhibits glucagon release and exerts a dual action on insulin release from isolated islets. Regulatory Peptides 111 55–60.
6. ↵
   1. Andersen B,
   2. Rassov A,
   3. Westergaard N &
   4. Lundgren K

   1999 Inhibition of glycogenolysis in primary rat hepatocytes by 1, 4-dideoxy-1,4-imino-d-arabinitol. Biochemical Journal 342 545–550.
7. ↵
   1. Andrews SS,
   2. Lopez-S A &
   3. Blackard WG

   1975 Effect of lipids on glucagon secretion in man. Metabolism 24 35–44.
8. ↵
   1. Asplin C,
   2. Raghu P,
   3. Dornan T &
   4. Palmer JP

   1983 Glucose regulation of glucagon secretion independent of B cell activity. Metabolism 32 292–295.
9. ↵
   1. Bailey SJ,
   2. Ravier MA &
   3. Rutter GA

   2007 Glucose-dependent regulation of gamma-aminobutyric acid (GABA A) receptor expression in mouse pancreatic islet alpha-cells. Diabetes 56 320–327.
10. ↵
    1. Balkan B &
    2. Li X

    2000 Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 279 R1449–R1454.
11. ↵
    1. Band GC &
    2. Jones CT

    1980 Functional activation by glucagon of glucose 6-phosphatase and gluconeogenesis in the perfused liver of the fetal guinea pig. FEBS Letters 119 190–194.
12. ↵
    1. Barg S,
    2. Galvanovskis J,
    3. Gopel SO,
    4. Rorsman P &
    5. Eliasson L

    2000 Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting alpha-cells. Diabetes 49 1500–1510.
13. ↵
    1. Baron AD,
    2. Schaeffer L,
    3. Shragg P &
    4. Kolterman OG

    1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36 274–283.
14. ↵
    1. Bertrand G,
    2. Gross R,
    3. Puech R,
    4. Loubatieres-Mariani MM &
    5. Bockaert J

    1993 Glutamate stimulates glucagon secretion via an excitatory amino acid receptor of the AMPA subtype in rat pancreas. European Journal of Pharmacology 237 45–50.
15. ↵
    1. Berts A,
    2. Gylfe E &
    3. Hellman B

    1997 Cytoplasmic Ca²⁺ in glucagon-producing pancreatic alpha-cells exposed to carbachol and agents affecting Na⁺ fluxes. Endocrine 6 79–83.
16. ↵
    1. Bohannon NV,
    2. Lorenzi M,
    3. Grodsky GM &
    4. Karam JH

    1982 Stimulatory effects of tolbutamide infusion on plasma glucagon in insulin-dependent diabetic subjects. Journal of Clinical Endocrinology and Metabolism 54 459–462.
17. ↵
    1. Bokvist K,
    2. Olsen HL,
    3. Hoy M,
    4. Gotfredsen CF,
    5. Holmes WF,
    6. Buschard K,
    7. Rorsman P &
    8. Gromada J

    1999 Characterisation of sulphonylurea and ATP-regulated K⁺ channels in rat pancreatic A-cells. Pflugers Archiv: European Journal of Physiology 438 428–436.
18. ↵
    1. Bollheimer LC,
    2. Landauer HC,
    3. Troll S,
    4. Schweimer J,
    5. Wrede CE,
    6. Scholmerich J &
    7. Buettner R

    2004 Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations. Metabolism 53 1443–1448.
19. ↵
    1. Bolli GB,
    2. Tsalikian E,
    3. Haymond MW,
    4. Cryer PE &
    5. Gerich JE

    1984 Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. Journal of Clinical Investigation 73 1532–1541.
20. ↵
    1. Samols E

    1. Bonner-Weir S

    1991Anatomy of the islet of Langerhans. In The Endocrine Pancreas, pp 15–28. Eds Samols E. New York: Raven Press.
21. ↵
    1. Borg WP,
    2. During MJ,
    3. Sherwin RS,
    4. Borg MA,
    5. Brines ML &
    6. Shulman GI

    1994 Ventromedial hypothalamic lesions in rats suppress counterregulatory responses to hypoglycemia. Journal of Clinical Investigation 93 1677–1682.
22. ↵
    1. Brelje TC,
    2. Scharp DW &
    3. Sorenson RL

    1989 Three-dimensional imaging of intact isolated islets of Langerhans with confocal microscopy. Diabetes 38 808–814.
23. ↵
    1. Brissova M,
    2. Fowler MJ,
    3. Nicholson WE,
    4. Chu A,
    5. Hirshberg B,
    6. Harlan DM &
    7. Powers AC

    2005 Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. Journal of Histochemistry and Cytochemistry 53 1087–1097.
24. ↵
    1. Cabrera O,
    2. Berman DM,
    3. Kenyon NS,
    4. Ricordi C,
    5. Berggren PO &
    6. Caicedo A

    2006 The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. PNAS 103 2334–2339.
25. ↵
    1. Cabrera O,
    2. Jacques-Silva MC,
    3. Speier S,
    4. Yang SN,
    5. Köhler M,
    6. Fachado A,
    7. Vieira E,
    8. Zierath JR,
    9. Kibbey R,
    10. Berman DM
    11. et al.

    2008 Glutamate is a positive autocrine signal for glucagon release. Cell Metabolism 7 545–554.
26. ↵
    1. Carlson MG,
    2. Snead WL &
    3. Campbell PJ

    1993 Regulation of free fatty acid metabolism by glucagon. Journal of Clinical Endocrinology and Metabolism 77 11–15.
27. ↵
    1. Chastain MA

    2001 The glucagonoma syndrome: a review of its features and discussion of new perspectives. American Journal of the Medical Sciences 321 306–320.
28. ↵
    1. Ciudad C,
    2. Camici M,
    3. Ahmad Z,
    4. Wang Y,
    5. DePaoli-Roach AA &
    6. Roach PJ

    1984 Control of glycogen synthase phosphorylation in isolated rat hepatocytes by epinephrine, vasopressin and glucagon. European Journal of Biochemistry 142 511–520.
29. ↵
    1. Consoli A,
    2. Nurjhan N,
    3. Capani F &
    4. Gerich J

    1989 Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38 550–557.
30. ↵
    1. Cryer PE

    2002 Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45 937–948.
31. ↵
    1. Cynober LA

    2002 Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 18 761–766.
32. ↵
    1. Dallas-Yang Q,
    2. Shen X,
    3. Strowski M,
    4. Brady E,
    5. Saperstein R,
    6. Gibson RE,
    7. Szalkowski D,
    8. Qureshi SA,
    9. Candelore MR,
    10. Fenyk-Melody JE
    11. et al.

    2004 Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. European Journal of Pharmacology 501 225–234.
33. ↵
    1. Degn KB,
    2. Brock B,
    3. Juhl CB,
    4. Djurhuus CB,
    5. Grubert J,
    6. Kim D,
    7. Han J,
    8. Taylor K,
    9. Fineman M &
    10. Schmitz O

    2004 Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53 2397–2403.
34. ↵
    1. Detimary P,
    2. Dejonghe S,
    3. Ling Z,
    4. Pipeleers D,
    5. Schuit F &
    6. Henquin JC

    1998 The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in beta cells but not in alpha cells and are also observed in human islets. Journal of Biological Chemistry 273 33905–33908.
35. ↵
    1. Dey A,
    2. Lipkind GM,
    3. Rouille Y,
    4. Norrbom C,
    5. Stein J,
    6. Zhang C,
    7. Carroll R &
    8. Steiner DF

    2005 Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon. Endocrinology 146 713–727.
36. ↵
    1. Diao J,
    2. Asghar Z,
    3. Chan CB &
    4. Wheeler MB

    2005 Glucose-regulated glucagon secretion requires insulin receptor expression in pancreatic α-cells. Journal of Biological Chemistry 280 33487–33496.
37. ↵
    1. Ding WG,
    2. Renstrom E,
    3. Rorsman P,
    4. Buschard K &
    5. Gromada J

    1997 Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca²⁺-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46 792–800.
38. ↵
    1. Dinneen S,
    2. Alzaid A,
    3. Turk D &
    4. Rizza R

    1995 Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38 337–343.
39. ↵
    1. Dumonteil E,
    2. Magnan C,
    3. Ritz-Laser B,
    4. Meda P,
    5. Dussoix P,
    6. Gilbert M,
    7. Ktorza A &
    8. Philippe J

    1998 Insulin, but not glucose lowering corrects the hyperglucagonemia and increased proglucagon messenger ribonucleic acid levels observed in insulinopenic diabetes. Endocrinology 139 4540–4546.
40. ↵
    1. Dumonteil E,
    2. Ritz-Laser B,
    3. Magnan C,
    4. Grigorescu I,
    5. Ktorza A &
    6. Philippe J

    1999 Chronic exposure to high glucose concentrations increases proglucagon messenger ribonucleic acid levels and glucagon release from InR1G9 cells. Endocrinology 140 4644–4650.
41. ↵
    1. Dumonteil E,
    2. Magnan C,
    3. Ritz-Laser B,
    4. Ktorza A,
    5. Meda P &
    6. Philippe J

    2000 Glucose regulates proinsulin and prosomatostatin but not proglucagon messenger ribonucleic acid levels in rat pancreatic islets. Endocrinology 141 174–180.
42. ↵
    1. Dunning BE &
    2. Gerich JE

    2007 The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocrine Reviews 28 253–283.
43. ↵
    1. Dunning BE,
    2. Foley JE &
    3. Ahrén B

    2005 Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 48 1700–1713.
44. ↵
    1. Eledrisi MS,
    2. Alshanti MS,
    3. Shah MF,
    4. Brolosy B &
    5. Jaha N

    2006 Overview of the diagnosis and management of diabetic ketoacidosis. American Journal of the Medical Sciences 331 243–251.
45. ↵
    1. Fehmann HC,
    2. Strowski M &
    3. Goke B

    1995 Functional characterization of somatostatin receptors expressed on hamster glucagonoma cells. American Journal of Physiology. Endocrinology and Metabolism 268 E40–E47.
46. ↵
    1. Franklin I,
    2. Gromada J,
    3. Gjinovci A,
    4. Theander S &
    5. Wollheim CB

    2005 β-cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54 1808–1815.
47. ↵
    1. Furuta M,
    2. Zhou A,
    3. Webb G,
    4. Carroll R,
    5. Ravazzola M,
    6. Orci L &
    7. Steiner DF

    2001 Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. Journal of Biological Chemistry 276 27197–27202.
48. ↵
    1. Gastaldelli A,
    2. Baldi S,
    3. Pettiti M,
    4. Toschi E,
    5. Camastra S,
    6. Natali A,
    7. Landau BR &
    8. Ferrannini E

    2000 Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49 1367–1373.
49. ↵
    1. Gedulin BR,
    2. Jodka CM,
    3. Herrmann K &
    4. Young AA

    2006 Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187. Regulatory Peptides 137 121–127.
50. ↵
    1. Gelling RW,
    2. Du XQ,
    3. Dichmann DS,
    4. Romer J,
    5. Huang H,
    6. Cui L,
    7. Obici S,
    8. Tang B,
    9. Holst JJ,
    10. Fledelius C
    11. et al.

    2003 Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. PNAS 100 1438–1443.
51. ↵
    1. Gopel S,
    2. Kanno T,
    3. Barg S,
    4. Galvanovskis J &
    5. Rorsman P

    1999 Voltage-gated and resting membrane currents recorded from β-cells in intact mouse pancreatic islets. Journal of Physiology 521 717–728.
52. ↵
    1. Gopel SO,
    2. Kanno T,
    3. Barg S &
    4. Rorsman P

    2000 Patch-clamp characterisation of somatostatin-secreting delta-cells in intact mouse pancreatic islets. Journal of Physiology 528 497–507.
53. ↵
    1. Gorus FK,
    2. Malaisse WJ &
    3. Pipeleers DG

    1984 Differences in glucose handling by pancreatic A- and B-cells. Journal of Biological Chemistry 259 1196–1200.
54. ↵
    1. Grapengiesser E,
    2. Salehi A,
    3. Qader SS &
    4. Hellman B

    2006 Glucose induces glucagon release pulses antisynchronous with insulin and sensitive to purinoceptor inhibition. Endocrinology 147 3472–3477.
55. ↵
    1. Gravholt CH,
    2. Moller N,
    3. Jensen MD,
    4. Christiansen JS &
    5. Schmitz O

    2001 Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. Journal of Clinical Endocrinology and Metabolism 86 2085–2089.
56. ↵
    1. Gremlich S,
    2. Bonny C,
    3. Waeber G &
    4. Thorens B

    1997 Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. Journal of Biological Chemistry 272 30261–30269.
57. ↵
    1. Gromada J,
    2. Bokvist K,
    3. Ding WG,
    4. Barg S,
    5. Buschard K,
    6. Renstrom E &
    7. Rorsman P

    1997 Adrenaline stimulates glucagon secretion in pancreatic A-cells by increasing the Ca²⁺ current and the number of granules close to the L-type Ca²⁺ channels. Journal of General Physiology 110 217–228.
58. ↵
    1. Gromada J,
    2. Hoy M,
    3. Buschard K,
    4. Salehi A &
    5. Rorsman P

    2001 Somatostatin inhibits exocytosis in rat pancreatic α-cells by Gi2-dependent activation of calcineurin and depriming of secretory granules. Journal of Physiology 535 519–532.
59. ↵
    1. Gromada J,
    2. Ma X,
    3. Hoy M,
    4. Bokvist K,
    5. Salehi A,
    6. Berggren PO &
    7. Rorsman P

    ATP-sensitive K⁺ channel-dependent regulation of glucagon release and electrical activity by glucose in wild-type and SUR1−/− mouse alpha-cellsDiabetes 53 Suppl 3 2004 S181–S189.
60. ↵
    1. Gromada J,
    2. Franklin I &
    3. Wollheim CB

    2007 Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocrine Reviews 28 84–116.
61. ↵
    1. Guenifi A,
    2. Ahren B &
    3. Abdel-Halim SM

    2001 Differential effects of glucagon-like peptide-1 (7–36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. Pancreas 22 58–64.
62. ↵
    1. Gyulkhandanyan AV,
    2. Lu H,
    3. Lee SC,
    4. Bhattacharjee A,
    5. Wijesekara N,
    6. Fox JE,
    7. MacDonald PE,
    8. Chimienti F,
    9. Dai FF &
    10. Wheeler MB

    2008 Investigation of transport mechanisms and regulation of intracellular Zn²⁺ in pancreatic α-cells. Journal of Biological Chemistry 283 10184–10197.
63. ↵
    1. Hayashi M,
    2. Otsuka M,
    3. Morimoto R,
    4. Muroyama A,
    5. Uehara S,
    6. Yamamoto A &
    7. Moriyama Y

    2003a Vesicular inhibitory amino acid transporter is present in glucagon-containing secretory granules in alphaTC6 cells, mouse clonal alpha-cells, and alpha-cells of islets of Langerhans. Diabetes 52 2066–2074.
64. ↵
    1. Hayashi M,
    2. Yamada H,
    3. Uehara S,
    4. Morimoto R,
    5. Muroyama A,
    6. Yatsushiro S,
    7. Takeda J,
    8. Yamamoto A &
    9. Moriyama Y

    2003b Secretory granule-mediated co-secretion of l-glutamate and glucagon triggers glutamatergic signal transmission in islets of Langerhans. Journal of Biological Chemistry 278 1966–1974.
65. ↵
    1. Heimberg H,
    2. De Vos A,
    3. Pipeleers D,
    4. Thorens B &
    5. Schuit F

    1995 Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization. Journal of Biological Chemistry 270 8971–8975.
66. ↵
    1. Heimberg H,
    2. De Vos A,
    3. Moens K,
    4. Quartier E,
    5. Bouwens L,
    6. Pipeleers D,
    7. Van Schaftingen E,
    8. Madsen O &
    9. Schuit F

    1996 The glucose sensor protein glucokinase is expressed in glucagon-producing alpha α-cells. PNAS 93 7036–7041.
67. ↵
    1. Herzig S,
    2. Long F,
    3. Jhala US,
    4. Hedrick S,
    5. Quinn R,
    6. Bauer A,
    7. Rudolph D,
    8. Schutz G,
    9. Yoon C,
    10. Puigserver P
    11. et al.

    2001 CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413 179–183.
68. ↵
    1. Hjorth SA,
    2. Adelhorst K,
    3. Pedersen BB,
    4. Kirk O &
    5. Schwartz TW

    1994 Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. Journal of Biological Chemistry 269 30121–30124.
69. ↵
    1. Hong J,
    2. Abudula R,
    3. Chen J,
    4. Jeppesen PB,
    5. Dyrskog SEU,
    6. Xiao J,
    7. Colombo M &
    8. Hermansen K

    2005 The short-term effect of fatty acids on glucagon secretion is influenced by their chain length, spatial configuration, and degree of unsaturation: studies in vitro. Metabolism 54 1329–1336.
70. ↵
    1. Hong J,
    2. Jeppesen PB,
    3. Nordentoft I &
    4. Hermansen K

    2007 Fatty acid-induced effect on glucagon secretion is mediated via fatty acid oxidation. Diabetes/Metabolism Research and Reviews 23 202–210.
71. ↵
    1. Hoy M,
    2. Bokvist K,
    3. Xiao-Gang W,
    4. Hansen J,
    5. Juhl K,
    6. Berggren PO,
    7. Buschard K &
    8. Gromada J

    2001 Phentolamine inhibits exocytosis of glucagon by Gi2 protein-dependent activation of calcineurin in rat pancreatic alpha-cells. Journal of Biological Chemistry 276 924–930.
72. ↵
    1. Hunyady B,
    2. Hipkin RW,
    3. Schonbrunn A &
    4. Mezey E

    1997 Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. Endocrinology 138 2632–2635.
73. ↵
    1. Inagaki N,
    2. Kuromi H,
    3. Gonoi T,
    4. Okamoto Y,
    5. Ishida H,
    6. Seino Y,
    7. Kaneko T,
    8. Iwanaga T &
    9. Seino S

    1995 Expression and role of ionotropic glutamate receptors in pancreatic islet cells. FASEB Journal 9 686–691.
74. ↵
    1. Ishihara H,
    2. Maechler P,
    3. Gjinovci A,
    4. Herrera PL &
    5. Wollheim CB

    2003 Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nature Cell Biology 5 330–335.
75. ↵
    1. Juhl CB,
    2. Hollingdal M,
    3. Sturis J,
    4. Jakobsen G,
    5. Agerso H,
    6. Veldhuis J,
    7. Porksen N &
    8. Schmitz O

    2002 Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51 424–429.
76. ↵
    1. Kaneko K,
    2. Shirotani T,
    3. Araki E,
    4. Matsumoto K,
    5. Taguchi T,
    6. Motoshima H,
    7. Yoshizato K,
    8. Kishikawa H &
    9. Shichiri M

    1999 Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells. Diabetes Research and Clinical Practice 44 83–92.
77. ↵
    1. Kendall DM,
    2. Poitout V,
    3. Olson LK,
    4. Sorenson RL &
    5. Robertson RP

    1995 Somatostatin coordinately regulates glucagon gene expression and exocytosis in HIT-T15 cells. Journal of Clinical Investigation 96 2496–2502.
78. ↵
    1. Kuhara T,
    2. Ikeda S,
    3. Ohneda A &
    4. Sasaki Y

    1991 Effects of intravenous infusion of 17 amino acids on the secretion of GH, glucagon, and insulin in sheep. American Journal of Physiology. Endocrinology and Metabolism 260 E21–E26.
79. ↵
    1. Kumar U,
    2. Sasi R,
    3. Suresh S,
    4. Patel A,
    5. Thangaraju M,
    6. Metrakos P,
    7. Patel SC &
    8. Patel YC

    1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48 77–85.
80. ↵
    1. Kurland IJ &
    2. Pilkis SJ

    1995 Covalent control of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: insights into autoregulation of a bifunctional enzyme. Protein Science 4 1023–1037.
81. ↵
    1. Landstedt-Hallin L,
    2. Adamson U &
    3. Lins PE

    1999 Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 84 3140–3145.
82. ↵
    1. Larsson H &
    2. Ahren B

    2000 Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23 650–657.
83. ↵
    1. Leclercq-Meyer V,
    2. Marchand J,
    3. Woussen-Colle MC,
    4. Giroix MH &
    5. Malaisse WJ

    1985 Multiple effects of leucine on glucagon, insulin, and somatostatin secretion from the perfused rat pancreas. Endocrinology 116 1168–1174.
84. ↵
    1. Leung YM,
    2. Ahmed I,
    3. Sheu L,
    4. Tsushima RG,
    5. Diamant NE,
    6. Hara M &
    7. Gaisano HY

    2005 Electrophysiological characterization of pancreatic islet cells in the mouse insulin promoter-green fluorescent protein mouse. Endocrinology 146 4766–4775.
85. ↵
    1. Leung YM,
    2. Ahmed I,
    3. Sheu L,
    4. Gao X,
    5. Hara M,
    6. Tsushima RG,
    7. Diamant NE &
    8. Gaisano HY

    2006 Insulin regulates islet α-cell function by reducing KATP channel sensitivity to adenosine 5′-triphosphate inhibition. Endocrinology 147 2155–2162.
86. ↵
    1. Li Y,
    2. Cao X,
    3. Li LX,
    4. Brubaker PL,
    5. Edlund H &
    6. Drucker DJ

    2005 Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 482–491.
87. ↵
    1. Li XC,
    2. Liao TD &
    3. Zhuo JL

    2008 Long-term hyperglucagonaemia induces early metabolic and renal phenotypes of Type 2 diabetes in mice. Clinical Science 114 591–601.
88. ↵
    1. Liang Y,
    2. Osborne MC,
    3. Monia BP,
    4. Bhanot S,
    5. Gaarde WA,
    6. Reed C,
    7. She P,
    8. Jetton TL &
    9. Demarest KT

    2004 Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53 410–417.
89. ↵
    1. Liu YJ,
    2. Vieira E &
    3. Gylfe E

    2004 A store-operated mechanism determines the activity of the electrically excitable glucagon-secreting pancreatic alpha-cell. Cell Calcium 35 357–365.
90. ↵
    1. Loubatieres AL,
    2. Loubatieres-Mariani MM,
    3. Alric R &
    4. Ribes G

    1974 Tolbutamide and glucagon secretion. Diabetologia 10 271–276.
91. ↵
    1. Ma X,
    2. Zhang Y,
    3. Gromada J,
    4. Sewing S,
    5. Berggren PO,
    6. Buschard K,
    7. Salehi A,
    8. Vikman J,
    9. Rorsman P &
    10. Eliasson L

    2005 Glucagon stimulates exocytosis in mouse and rat pancreatic alpha-cells by binding to glucagon receptors. Molecular Endocrinology 19 198–212.
92. ↵
    1. MacDonald PE,
    2. De Marinis YZ,
    3. Ramracheya R,
    4. Salehi A,
    5. Ma X,
    6. Johnson PR,
    7. Cox R,
    8. Eliasson L &
    9. Rorsman P

    2007 A K ATP channel-dependent pathway within alpha cells regulates glucagon release from both rodent and human islets of Langerhans. PLoS Biology 5 e143.
93. ↵
    1. Manning Fox JE,
    2. Gyulkhandanyan AV,
    3. Satin LS &
    4. Wheeler MB

    2006 Oscillatory membrane potential response to glucose in islet beta-cells: a comparison of islet-cell electrical activity in mouse and rat. Endocrinology 147 4655–4663.
94. ↵
    1. Mayo KE,
    2. Miller LJ,
    3. Bataille D,
    4. Dalle S,
    5. Goke B,
    6. Thorens B &
    7. Drucker DJ

    2003 International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacological Reviews 55 167–194.
95. ↵
    1. McGirr R,
    2. Ejbick CE,
    3. Carter DE,
    4. Andrews JD,
    5. Nie Y,
    6. Friedman TC &
    7. Dhanvantari S

    2005 Glucose dependence of the regulated secretory pathway in alphaTC1-6 cells. Endocrinology 146 4514–4523.
96. ↵
    1. Miki T,
    2. Liss B,
    3. Minami K,
    4. Shiuchi T,
    5. Saraya A,
    6. Kashima Y,
    7. Horiuchi M,
    8. Ashcroft F,
    9. Minokoshi Y,
    10. Roeper J
    11. et al.

    2001 ATP-sensitive K⁺ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nature Neuroscience 4 507–512.
97. ↵
    1. Mojsov S,
    2. Heinrich G,
    3. Wilson IB,
    4. Ravazzola M,
    5. Orci L &
    6. Habener JF

    1986 Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. Journal of Biological Chemistry 261 11880–11889.
98. ↵
    1. Munoz A,
    2. Hu M,
    3. Hussain K,
    4. Bryan J,
    5. Aguilar-Bryan L &
    6. Rajan AS

    2005 Regulation of glucagon secretion at low glucose concentrations: evidence for adenosine triphosphate-sensitive potassium channel involvement. Endocrinology 146 5514–5521.
99. ↵
    1. Nadal A,
    2. Quesada I &
    3. Soria B

    1999 Homologous and heterologous asynchronicity between identified alpha-, beta- and delta-cells within intact islets of Langerhans in the mouse. Journal of Physiology 517 85–93.
100. ↵
     1. Nauck MA,
     2. Heimesaat MM,
     3. Behle K,
     4. Holst JJ,
     5. Nauck MS,
     6. Ritzel R,
     7. Hufner M &
     8. Schmiegel WH

     2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 87 1239–1246.
101. ↵
     1. Olofsson CS,
     2. Salehi A,
     3. Gopel SO,
     4. Holm C &
     5. Rorsman P

     2004 Palmitate stimulation of glucagon secretion in mouse pancreatic alpha-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium. Diabetes 53 2836–2843.
102. ↵
     1. Olsen HL,
     2. Theander S,
     3. Bokvist K,
     4. Buschard K,
     5. Wollheim CB &
     6. Gromada J

     2005 Glucose stimulates glucagon release in single rat alpha-cells by mechanisms that mirror the stimulus-secretion coupling in beta-cells. Endocrinology 146 4861–4870.
103. ↵
     1. Ostenson CG,
     2. Nylen A,
     3. Grill V,
     4. Gutniak M &
     5. Efendic S

     1986 Sulfonylurea-induced inhibition of glucagon secretion from the perfused rat pancreas: evidence for a direct, non-paracrine effect. Diabetologia 29 861–867.
104. ↵
     1. Paty BW,
     2. Ryan EA,
     3. Shapiro AM,
     4. Lakey JR &
     5. Robertson RP

     2002 Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counterregulation or symptom recognition after insulin independence. Diabetes 51 3428–3434.
105. ↵
     1. Paul GL,
     2. Waegner A,
     3. Gaskins HR &
     4. Shay NF

     1998 Histidine availability alters glucagon gene expression in murine alphaTC6 cells. Journal of Nutrition 128 973–976.
106. ↵
     1. Pereverzev A,
     2. Salehi A,
     3. Mikhna M,
     4. Renstrom E,
     5. Hescheler J,
     6. Weiergraber M,
     7. Smyth N &
     8. Schneider T

     2005 The ablation of the Ca(v)2.3/E-type voltage-gated Ca²⁺ channel causes a mild phenotype despite an altered glucose induced glucagon response in isolated islets of Langerhans. European Journal of Pharmacology 511 65–72.
107. ↵
     1. Petersen KF &
     2. Sullivan JT

     2001 Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44 2018–2024.
108. ↵
     1. Philippe J,
     2. Morel C &
     3. Cordier-Bussat M

     1995 Islet-specific proteins interact with the insulin-response element of the glucagon gene. Journal of Biological Chemistry 270 3039–3045.
109. ↵
     1. Pipeleers DG,
     2. Schuit FC,
     3. Van Schravendijk CF &
     4. Van de Winkel M

     1985 Interplay of nutrients and hormones in the regulation of glucagon release. Endocrinology 117 817–823.
110. ↵
     1. Quesada I,
     2. Nadal A &
     3. Soria B

     1999 Different effects of tolbutamide and diazoxide in alpha, beta-, and delta-cells within intact islets of Langerhans. Diabetes 48 2390–2397.
111. ↵
     1. Quesada I,
     2. Fuentes E,
     3. Andreu E,
     4. Meda P,
     5. Nadal A &
     6. Soria B

     2003 On-line analysis of gap junctions reveals more efficient electrical than dye coupling between islet cells. American Journal of Physiology. Endocrinology and Metabolism 284 E980–E987.
112. ↵
     1. Quesada I,
     2. Todorova MG &
     3. Soria B

     2006a Different metabolic responses in α-β-, and δ-cells of the islet of Langerhans monitored by redox confocal microscopy. Biophysical Journal 90 2641–2650.
113. ↵
     1. Quesada I,
     2. Todorova MG,
     3. Alonso-Magdalena P,
     4. Beltra M,
     5. Carneiro EM,
     6. Martin F,
     7. Nadal A &
     8. Soria B

     2006b Glucose induces opposite intracellular Ca²⁺ concentration oscillatory patterns in identified α- and β-cells within intact human islets of Langerhans. Diabetes 55 2463–2469.
114. ↵
     1. Quoix N,
     2. Cheng-Xue R,
     3. Guiot Y,
     4. Herrera PL,
     5. Henquin JC &
     6. Gilon P

     2007 The GluCre-ROSA26EYFP mouse: a new model for easy identification of living pancreatic alpha-cells. FEBS Letters 581 4235–4240.
115. ↵
     1. Qureshi SA,
     2. Rios CM,
     3. Xie D,
     4. Yang X,
     5. Tota LM,
     6. Ding VD,
     7. Li Z,
     8. Bansal A,
     9. Miller C,
     10. Cohen SM
     11. et al.

     2004 A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53 3267–3273.
116. ↵
     1. Ravier MA &
     2. Rutter GA

     2005 Glucose or insulin, but not zinc ions, inhibit glucagon secretion from mouse pancreatic alpha-cells. Diabetes 54 1789–1797.
117. ↵
     1. Reaven GM,
     2. Chen YD,
     3. Golay A,
     4. Swislocki AL &
     5. Jaspan JB

     1987 Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 64 106–110.
118. ↵
     1. Rorsman P,
     2. Berggren PO,
     3. Bokvist K,
     4. Ericson H,
     5. Mohler H,
     6. Ostenson CG &
     7. Smith PA

     1989 Glucose-inhibition of glucagon secretion involves activation of GABAA-receptor chloride channels. Nature 341 233–236.
119. ↵
     1. Rosenstock J,
     2. Baron MA,
     3. Dejager S,
     4. Mills D &
     5. Schweizer A

     2007 Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30 217–223.
120. ↵
     1. Schuit FC,
     2. Derde MP &
     3. Pipeleers DG

     1989 Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia 32 207–212.
121. ↵
     1. Schuit F,
     2. De Vos A,
     3. Farfari S,
     4. Moens K,
     5. Pipeleers D,
     6. Brun T &
     7. Prentki M

     1997 Metabolic fate of glucose in purified islet cells. Glucose-regulated anaplerosis in beta cells. Journal of Biological Chemistry 272 18572–18579.
122. ↵
     1. Sekine N,
     2. Cirulli V,
     3. Regazzi R,
     4. Brown LJ,
     5. Gine E,
     6. Tamarit-Rodriguez J,
     7. Girotti M,
     8. Marie S,
     9. MacDonald MJ,
     10. Wollheim CB
     11. et al.

     1994 Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogenase in pancreatic beta-cells. Potential role in nutrient sensing. Journal of Biological Chemistry 269 4895–4902.
123. ↵
     1. Shah P,
     2. Basu A,
     3. Basu R &
     4. Rizza R

     1999 Impact of lack of suppression of glucagon on glucose tolerance in humans. American Journal of Physiology 277 E283–E290.
124. ↵
     1. Shah P,
     2. Vella A,
     3. Basu A,
     4. Basu R,
     5. Schwenk WF &
     6. Rizza RA

     2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 85 4053–4059.
125. ↵
     1. Shiota C,
     2. Rocheleau JV,
     3. Shiota M,
     4. Piston DW &
     5. Magnuson MA

     2005 Impaired glucagon secretory responses in mice lacking the type 1 sulfonylurea receptor. American Journal of Physiology. Endocrinology and Metabolism 289 E570–E577.
126. ↵
     1. Singh V,
     2. Brendel MD,
     3. Zacharias S,
     4. Mergler S,
     5. Jahr H,
     6. Wiedenmann B,
     7. Bretzel RG,
     8. Plockinger U &
     9. Strowski MZ

     2007 Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. Journal of Clinical Endocrinology and Metabolism 92 673–680.
127. ↵
     1. Slavin BG,
     2. Ong JM &
     3. Kern PA

     1994 Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes. Journal of Lipid Research 35 1535–1541.
128. ↵
     1. Sloop KW,
     2. Cao JX,
     3. Siesky AM,
     4. Zhang HY,
     5. Bodenmiller DM,
     6. Cox AL,
     7. Jacobs SJ,
     8. Moyers JS,
     9. Owens RA,
     10. Showalter AD
     11. et al.

     2004 Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. Journal of Clinical Investigation 113 1571–1581.
129. ↵
     1. Song Z,
     2. Levin BE,
     3. McArdle JJ,
     4. Bakhos N &
     5. Routh VH

     2001 Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus. Diabetes 50 2673–2681.
130. ↵
     1. Sorensen H,
     2. Brand CL,
     3. Neschen S,
     4. Holst JJ,
     5. Fosgerau K,
     6. Nishimura E &
     7. Shulman GI

     2006 Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55 2843–2848.
131. ↵
     1. Strowski MZ,
     2. Parmar RM,
     3. Blake AD &
     4. Schaeffer JM

     2000 Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141 111–117.
132. ↵
     1. Strowski MZ,
     2. Cashen DE,
     3. Birzin ET,
     4. Yang L,
     5. Singh V,
     6. Jacks TM,
     7. Nowak KW,
     8. Rohrer SP,
     9. Patchett AA,
     10. Smith RG
     11. et al.

     2006 Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist. Endocrinology 147 4664–4673.
133. ↵
     1. Van Tine BA,
     2. Azizeh BY,
     3. Trivedi D,
     4. Phelps JR,
     5. Houslay MD,
     6. Johnson DG &
     7. Hruby VJ

     1996 Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137 3316–3322.
134. ↵
     1. Tschritter O,
     2. Stumvoll M,
     3. Machicao F,
     4. Holzwarth M,
     5. Weisser M,
     6. Maerker E,
     7. Teigeler A,
     8. Haring H &
     9. Fritsche A

     2002 The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 51 2854–2860.
135. ↵
     1. Tudurí E,
     2. Filiputti E,
     3. Carneiro EM &
     4. Quesada I

     2008 Inhibition of Ca²⁺ signaling and glucagon secretion in mouse pancreatic alpha-cells by extracellular ATP and purinergic receptors. American Journal of Physiology. Endocrinology and Metabolism 294 E952–E960.
136. ↵
     1. Uehara S,
     2. Muroyama A,
     3. Echigo N,
     4. Morimoto R,
     5. Otsuka M,
     6. Yatsushiro S &
     7. Moriyama Y

     2004 Metabotropic glutamate receptor Type 4 is involved in autoinhibitory cascade for glucagon secretion by α-cells of islet of Langerhans. Diabetes 53 998–1006.
137. ↵
     1. Unger RH &
     2. Orci L

     1975 The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1 14–16.
138. ↵
     1. Vieira E,
     2. Salehi A &
     3. Gylfe E

     2007 Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. Diabetologia 50 370–379.
139. ↵
     1. Vons C,
     2. Pegorier JP,
     3. Girard J,
     4. Kohl C,
     5. Ivanov MA &
     6. Franco D

     1991 Regulation of fatty-acid metabolism by pancreatic hormones in cultured human hepatocytes. Hepatology 13 1126–1130.
140. ↵
     1. Vozzi C,
     2. Ullrich S,
     3. Charollais A,
     4. Philippe J,
     5. Orci L &
     6. Meda P

     1995 Adequate connexin-mediated coupling is required for proper insulin production. Journal of Cell Biology 131 1561–1572.
141. ↵
     1. Wakelam MJO,
     2. Murphy GJ,
     3. Hruby VJ &
     4. Houslay MD

     1986 Activation of two signal-transduction systems in hepatocytes by glucagon. Nature 323 68–71.
142. ↵
     1. Wang F,
     2. Adrian TE,
     3. Westermark GT,
     4. Ding X,
     5. Gasslander T &
     6. Permert J

     1999 Islet amyloid polypeptide tonally inhibits beta -, alpha -, and delta-cell secretion in isolated rat pancreatic islets. American Journal of Physiology. Endocrinology and Metabolism 276 E19–E24.
143. ↵
     1. Wendt A,
     2. Birnir B,
     3. Buschard K,
     4. Gromada J,
     5. Salehi A,
     6. Sewing S,
     7. Rorsman P &
     8. Braun M

     2004 Glucose inhibition of glucagon secretion from rat α-cells is mediated by GABA released from neighboring β-cells. Diabetes 53 1038–1045.
144. ↵
     1. Winzell MS,
     2. Brand CL,
     3. Wierup N,
     4. Sidelmann UG,
     5. Sundler F,
     6. Nishimura E &
     7. Ahren B

     2007 Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50 1453–1462.
145. ↵
     1. Xu E,
     2. Kumar M,
     3. Zhang Y,
     4. Ju W,
     5. Obata T,
     6. Zhang N,
     7. Liu S,
     8. Wendt A,
     9. Deng S &
     10. Ebina Y

     2006 Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metabolism 3 47–58.
146. ↵
     1. Yamato E,
     2. Noma Y,
     3. Tahara Y,
     4. Ikegami H,
     5. Yamamoto Y,
     6. Cha T,
     7. Yoneda H,
     8. Ogihara T,
     9. Ohboshi C,
     10. Hirota M
     11. et al.

     1990 Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets. Biochemical and Biophysical Research Communications 167 431–437.
147. ↵
     1. Yoon JC,
     2. Puigserver P,
     3. Chen G,
     4. Donovan J,
     5. Wu Z,
     6. Rhee J,
     7. Adelmant G,
     8. Stafford J,
     9. Kahn CR,
     10. Granner DK
     11. et al.

     2001 Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 131–138.
148. ↵
     1. Yoshimoto Y,
     2. Fukuyama Y,
     3. Horio Y,
     4. Inanobe A,
     5. Gotoh M &
     6. Kurachi Y

     1999 Somatostatin induces hyperpolarization in pancreatic islet [alpha] cells by activating a G protein-gated K⁺ channel. FEBS Letters 444 265–269.
149. ↵
     1. Young A

     2005 Inhibition of glucagon secretion. Advances in Pharmacology 52 151–171.
150. ↵
     1. Zaitsev SV,
     2. Efanov AM,
     3. Efanova IB,
     4. Larsson O,
     5. Ostenson CG,
     6. Gold G,
     7. Berggren PO &
     8. Efendic S

     1996 Imidazoline compounds stimulate insulin release by inhibition of K(ATP) channels and interaction with the exocytotic machinery. Diabetes 45 1610–1618.
151. ↵
     1. Zhao C,
     2. Wilson MC,
     3. Schuit F,
     4. Halestrap AP &
     5. Rutter GA

     2001 Expression and distribution of lactate/monocarboxylate transporter isoforms in pancreatic islets and the exocrine pancreas. Diabetes 50 361–366.
152. ↵
     1. Zhou H,
     2. Zhang T,
     3. Harmon JS,
     4. Bryan J &
     5. Robertson RP

     2007a Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo. Diabetes 56 1107–1112.
153. ↵
     1. Zhou H,
     2. Zhang T,
     3. Oseid E,
     4. Harmon J,
     5. Tonooka N &
     6. Robertson RP

     2007b Reversal of defective glucagon responses to hypoglycemia in insulin-dependent autoimmune diabetic BB rats. Endocrinology 148 2863–2869.